Minimally Invasive Surgery for Pancreatic Neuroendocrine Tumors: Why Not? Abstract #1024

Introduction: Recent evidence suggests that pancreatic neuroendocrine tumors (pNETs) are amenable to minimally invasive resections (MIPR).
Aim(s): To evaluate the efficacy of minimally invasive surgeries for pNETs.
Materials and methods: We performed a retrospective analysis of all minimally invasive pancreatic resections between January 2002 and November 2013. Operative, pathological and follow-up data were analyzed (standard statistical methods).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Surgical treatment
Presenting Author: doctor Anna Malpaga

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1839 Laparoscopic and Robotic Resection for Pancreatic Neuroendocrine Tumors (pNET): Less Is More?
Introduction: Laparoscopy is useful for the resection of pNET, but only a few studies in the Literature describes outcomes for a large series
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Surgical treatment
Presenting Author: DOCTOR Isacco Damoli
#2228 Prognostic Value of Lymph Node Status and Extent of Lymphadenectomy in Non Functioning Pancreatic Neuroendocrine Tumors: Outcome Analysis from 378 Consecutive Resections in a High-Volume Institution
Introduction: The optimal management of regional lymph nodes during resections of Pancreatic Neuroendocrine Tumors (pNETs) remains controversial. Conflicting data exist on predictors of LN metastases (LNM) and their impact on survival
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Surgical treatment and Ablative Therapies
Presenting Author: doctor Anna Malpaga
Authors: Malpaga A, Miotto M, Elio G, Nessi C, ...
#2986 Characterization of 142 Human Pancreatic Neuroendocrine Tumors: ATRX and DAXX Correlation with Clinical-Pathological Data
Introduction: Pancreatic neuroendocrine tumors (PNETs) are rare and heterogeneous neoplasms with a 10-year survival rate less than 30%. Up to 43% of them are driven by inactivating mutations in ATRX or DAXX. These are important players at chromatin remodeling, that when mutated prone cancer cells to initiate the alternative lengthening of telomeres (ALT). ALT phenotype correlates with in situ loss of expression of the proteins ATRX or DAXX and can be corroborated by telomere-FISH.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: DVM Tiago B Gaspar
#3082 MEN1 Associated pNETs: A Case Series from Two Centres of Excellence in the United Kingdom
Introduction: Literature on MEN1 associated PNETS as a unique clinico-pathological entity is evolving.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Hema Venkataraman
#2908 Re-Cellularised Human Pancreas 3D Scaffolds as a Novel Model for Biomarker Discovery in Pancreatic Neuroendocrine Tumours (pNETs)
Introduction: The lack of preclinical models of pNETs has challenged identification of tissue specific biomarkers of disease. Culturing cancer cells in their native tissue enables the close study of cell-ECM interaction and tissue remodelling. The biological products of such interactions can form a basis for discovery of novel biomarkers of the disease, and were previously linked with a range of inflammatory and malignant conditions.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: PhD student & CR Alexander Ney